South Korean lawmakers impeach second president in two weeks South Korean lawmakers chanting slogans in front of acting President Han Duck-soo. — AFP/File SEOUL: South Korean lawmakers impeached acting president Han Duck-soo on Friday, sinking the country even deeper into political crisis two weeks after his predecessor was suspended over a martial law declaration that shocked the world. googletag.cmd.push(function() { googletag.display('div-gpt-ad-1700472799616-0'); }); Han, a career bureaucrat who was serving as prime minister, took over from President Yoon Suk Yeol on December 14 after parliament voted to impeach him on allegations of insurrection. Opposition MPs have now also stripped Han of his duties, arguing that he refused demands to complete Yoon ́s impeachment process and to bring him to justice. “I announce that Prime Minister Han Duck-soo ́s impeachment motion has passed. Out of the 192 lawmakers who voted, 192 voted to impeach,” said National Assembly Speaker Woo Won-shik. Lawmakers from the ruling People ́s Power Party (PPP) loudly protested in parliament after the speaker said only a simple majority was required for impeachment to pass, instead of the two-thirds required to remove Yoon. PPP lawmakers began chanting angrily, with many rushing towards Woo, demanding that he resign. They did not take part in the vote. In addition to being the second impeachment of a head of state in just two weeks, Friday ́s vote was also South Korea ́s first impeachment of an acting president. PPP leader Kweon Seong-dong said after the vote that Han “must continue to lead state affairs without yielding to the opposition ́s passage of the impeachment motion”. However, Han said in a statement that he “respects the parliament ́s decision” and would wait for the Constitutional Court ́s subsequent decision on whether to uphold it.The Foreign Ministry appointed Ambassador to Nouakchott Burhan Köroğlu as a temporary charge d'affaires for Türkiye's Embassy in Syria's capital Damascus in light of recent developments. The embassy was closed in March 2012 following clashes between Assad regime forces and pro-democracy protestors. The appointment of Köroğlu came shortly after Türkiye's top intelligence chief Ibrahim Kalın visited the Syrian capital on Thursday. Syria's anti-regime forces entered the capital Damascus early Sunday ending the Bashar Assad regime's decadeslong rule. The capture also overthrew the Baath Party, the Arab socialist group that had come to power in Syria in a 1963 coup. The anti-regime forces also dealt a major blow to the influence of Russia and Iran in Syria in the heart of the region, allies who propped up Assad during critical periods in the conflict. Türkiye, which said it gave no support and had no involvement in the offensive led by the Hayat Tahrir al-Sham (HTS), said it wanted the new Syrian administration to be inclusive and for Syrians to determine their own future. Ankara openly backed the Syrian opposition to the Assad regime since the unrest evolved into a civil war in the neighboring country more than a decade ago. Until Assad’s fall, Ankara sought to normalize ties with Damascus and find a political solution to the civil war. While several countries, including Egypt, Iraq and Italy, swiftly reopened their diplomatic missions in Damascus following the opposition offensive, Foreign Minister Hakan Fidan said Ankara was waiting for the “right conditions to emerge” to reopen its embassy in the Syrian capital. Dr. Köroğlu was appointed as ambassador to Mauritania in Dec. 2023. He completed his master's degree in Jordan and received his PhD in Islamic Philosophy from Marmara University. He worked as an academic in several universities and headed various research centers. He is fluent in English and Arabic.Crumly & Associates Inc. Raises Stock Position in Alphabet Inc. (NASDAQ:GOOGL)

Minneapolis, Minnesota, Dec. 03, 2024 (GLOBE NEWSWIRE) -- This January, Carolrhoda Booksâ, an imprint of Lerner Publishing Group TM , presents And, Too, the Fox by U.S. Poet Laureate Ada Limón and illustrated by Gaby D'Alessandro. First published in Limón's most recent poetry collection, The Hurting Kind , this poem blooms in picture book format and cultivates a sense of wonder and imagination in young readers observing the natural world. The fox meanders through a landscape set in Kentucky, Limón's home state. Flora and fauna from other poems in The Hurting Kind adorn every spread, incorporating more of Limón's work within the woodlands, prairie, and suburbs pictured. Readers watch the fox enjoy tender moments of rest in soft grasses, swift hunting on bouncy feet, and furious digging. Limón maintains a sense of respectful distance between the reader and the fox, pondering his unconcerned, private existence. Gentle, precise poetry meditates on the quiet spaces the fox inhabits, while D'Alessandro's fluid brushstrokes flush each page with life and movement. The artwork's use of light and color offer blushing sunsets, hazy blue skies, and mystic evenings which evoke a sense of magic in the world's most peaceful moments. This heartfelt story will appeal to poetry and nature lovers of all ages. Praise for And, Too, The Fox : "The wonder and reverence conveyed through the text and the fluidity of the illustrations result in a smooth and calming experience that will leave readers awed at the beauty of nature. A grounded yet ethereal blend of verse and vulpine sentiments."—starred, Kirkus Reviews "Children will be captivated by Fox as they join him on a joyful romp through his world."—starred, School Library Journal "In soaring lines of poetry that feel as graceful as the creature they describe, Limón ( In Praise of Mystery ) considers a fox seen in a fenced backyard . . . The sense of having entered the world of a wild animal for a few unexpected moments lingers in this refreshing picture book encounter."— Publishers Weekly About the Author and Illustrator: Ada Limón is the author of six books of poetry, including The Carrying , which won the National Book Critics Circle Award for Poetry. Her most recent book of poetry, The Hurting Kind , was shortlisted for the Griffin Poetry Prize. She is the 24th Poet Laureate of the United States and the recipient of a MacArthur Fellowship. As the Poet Laureate, her signature project is called You Are Here and focuses on how poetry can help connect us to the natural world. Gaby D'Alessandro is a Dominican illustrator based in NYC. She attended Altos de Chavón in the Dominican Republic and moved to New York to complete her studies at Parsons School of Design. Gaby's work has been recognized by Communication Arts , The Society of Illustrators , 3x3 , American Illustration, and Latin American Ilustración. Her illustrated books include The Cot in the Living Room and Stolen Science . About the Publisher: Carolrhoda Booksâ, an imprint of Lerner Publishing Group TM , has been publishing high-quality, award-winning books since 1959. Our picture books spark children's imaginations and offer new ways of looking at the world. Our middle-grade books stand out not only for their quality, but also for the breadth of genres encompassed, from coming-of-age stories to exceptional nonfiction to mysteries. Carolrhoda authors and illustrators have been honored with awards such as a Caldecott Honor, the Coretta Scott King Book Award, the Robert F. Sibert Informational Book Medal, and the Jane Addams Children's Book Award. We believe that all children should be able to find themselves in the pages of a book. Find us on all social media platforms at @LernerBooks and look inside at lernerbooks.com. And, Too, the Fox January 2025 $18.99 Hardcover, Jacketed eBook Also Available Ages 5 - 9 HC: 979-8-7656-3925- 2 32 Pages ● 9 3/4 x 9 3/4 Attachments And, Too, the Fox And, Too, the Fox © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.None

Kings fire coach Mike Brown less than halfway through his 3rd season, AP source says The Sacramento Kings have fired coach Mike Brown less than halfway through his third season with the team mired in a five-game losing streak, a person familiar with the decision told The Associated Press. The person spoke on condition of anonymity because the firing hadn’t been announced by the team. ESPN first reported the firing. Brown won NBA Coach of the Year in his first season in 2022-23, when he helped Sacramento end the longest playoff drought in NBA history at 16 seasons. But Sacramento lost in the play-in tournament last year and was off to a 13-18 start this season. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get any of our free email newsletters — news headlines, obituaries, sports, and more.Pregnant Charlotte Crosby hires security after being rushed to hospital amid burglary ordeal

AMMO Deadline: POWW Investors Have Opportunity to Lead AMMO, Inc. Securities Fraud Lawsuit

TORONTO and HAIFA, Israel, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies, has announced significant findings from an expanded preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing optic nerve damage. Conducted in collaboration with the Goldschleger Eye Institute at Sheba Medical Center, consistently ranked one of the top ten hospitals in the world 1 , the study builds on previously announced preliminary results 2 on June 28, 2024 and strengthens the suggestion of a promising treatment pathway for glaucoma, the leading cause of irreversible blindness globally 3 . The Optic Nerve Disorders treatment market is expected to grow from 5.54 (USD Billion) in 2023 to 11.5 (USD Billion) by 2032, at a compound annual growth rate (CAGR) of ~8.46% during the forecast period 4 . Researchers utilized a rodent model of optic nerve crush (ONC) to simulate the damage associated with conditions like glaucoma. After inducing injury, ExoPTEN was administrated via direct injection into the eyes. The study expanded on earlier findings which indicated that eyes treated with ExoPTEN regained nearly normal retinal activity, as evidenced by electrical tests. Expanded analyses of the study data showed clear recovery of signal transmission in treated eyes compared to untreated controls, which showed no significant response. Additionally, imaging results by optical coherence tomography (OCT) scans indicates and validates that in all of treated eyes (naïve exosome treatment or ExoPTEN treatment) a successful ONC procedure has been performed (Figure 1). The study also showed that ExoPTEN treatment significantly enhanced the survival of retinal ganglion cells - key neurons responsible for transmitting visual information to the brain. Detailed analysis of retinal flat-mounts confirmed this effect, with treated eyes exhibiting substantially higher counts of these cells compared to untreated or control-treated eyes (Figures 2A and 2B). Dr. Ifat Sher, the lead investigator from the Goldschleger Eye Institute, commented, “the results from this expanded study are extremely encouraging. ExoPTEN demonstrates potential as a treatment that restores functionality and offers neuroprotection. The study shows clear signal recovery, healthier optic nerve structures and preserved retinal ganglion cells. These results suggest that ExoPTEN could fundamentally change how we approach conditions like glaucoma and optic nerve trauma. Encouraged by these results, we are advancing to a larger study with more animals to validate and expand upon these findings.” Dr. Lior Shaltiel, CEO of NurExone, added, “these findings are an important step forward in our mission to develop groundbreaking therapies for regenerative medicine in several indications. ExoPTEN’s ability to repair both the structure and function of the optic nerve highlights its transformative potential for addressing vision loss and improving tens of millions of patient lives.” About NurExone NurExone Biologic Inc. is a TSX Venture Exchange (“ TSXV ”) and OTCQB listed pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, minimally-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). The NurExone platform technology is expected to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. For additional information and a brief interview, please watch Who is NurExone? , visit www.nurexone.com or follow NurExone on LinkedIn , X (formerly Twitter) , Facebook or YouTube Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Oak Hill Financial Inc. 2 Bloor Street, Suite 2900 Toronto, Ontario M4W 3E2 Investor Relations - Canada Phone: +1-647-479-5803 Email: info@oakhillfinancial.ca Dr. Eva Reuter Investor Relations - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu Allele Capital Partners Investor Relations - US Phone: +1 978-857-5075 Email: aeriksen@allelecapital.com FORWARD-LOOKING STATEMENTS This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the results of the Company’s preclinical trials and its suggestion of a promising treatment pathway for glaucoma; the growth of the Optic Nerve Disorders treatment market; the Company expanding to further studies; the Company developing groundbreaking therapies for regenerative medicine in several indications; ExoPTEN having the potential to address vision loss and improve patient lives; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including : the a bility to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the Company’s ability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company’s ability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine; the Optic Nerve Disorders treatment market continuing to grow as stated; the Company expanding to further studies; the Company developing groundbreaking therapies for regenerative medicine in several indications; ExoPTEN addressing vision loss and improve patient lives; and the NurExone platform technology will offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to : the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the Company’s inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company’s inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine; the Optic Nerve Disorders treatment market decreasing and/or plateauing ; the Company ’s inability to expand into further studies; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications ; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27 , 202 4 , a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca . These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. 1 https://www.afsmc.org/2024/02/sheba-medical-center-named-a-newsweek-worlds-best-hospital-for-the-6th-consecutive-year/ 2 https://www.globenewswire.com/news-release/2024/06/28/2906122/0/en/NurExone-s-ExoPTEN-Being-Studied-as-Glaucoma-Treatment-for-US-3-4-Billion-Market.html 3 https://www.mdpi.com/1424-8247/17/10/1261 4 https://www.marketresearchfuture.com/reports/optic-nerve-disorders-treatment-market-30051 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5e682a60-3287-44b2-b7da-08ebed8fa807CHICAGO — Newly unsealed court records now link embattled Chicago rapper Lil Durk — already facing murder-for-hire charges in Los Angeles — to the fatal 2022 shooting of an alleged gang leader outside a community center on Chicago’s Far South Side. The warrant application was filed in April 2023 but was not unsealed until Wednesday, in advance of a scheduled Thursday detention hearing in Lil Durk’s murder-for-hire case. Lil Durk — born Devontay Durk Banks — was charged last month with funding a cross-country murder-for-hire plan to exact revenge for the 2020 killing of fellow Chicago rapper King Von in Atlanta. The newly unsealed filing in U.S. District Court in Chicago alleges Banks was behind the Jan. 27, 2022 killing of Stephon Mack , 24, who was shot to death shortly after he exited the Youth Peace Center of Roseland on West 111th Street. At the time of his death, according to the FBI, Mack was the leader of the Smashville faction of the Gangster Disciples. Banks’ brother, Dontay Banks, was shot to death outside a nightclub in south suburban Harvey in 2021. According to the warrant application, another Gangster Disciples faction with ties to Smashville carried out the murder. “Lil Durk was and still is offering money for people to kill those responsible for his brother’s murder, and more specifically, offering to pay money for any Gangster Disciple that is killed,” a federal agent wrote in April 2023. Banks has not been charged in the Chicago investigation, which law enforcement sources told the Tribune is still open and active. Earlier this year, federal prosecutors in Chicago charged two men, Anthony Montgomery-Wilson and Preston Powell, with conspiracy to commit murder-for-hire in Mack’s killing. Banks, though, is not charged in Mack’s death. Federal prosecutors in Los Angeles are expected to point to the shooting as reason to keep Banks in police custody before trial. In probing Mack’s death, federal investigators analyzed jail phone calls, social media postings, firearms purchases, as well as lyrics from Lil Durk’s song “Ahhh Ha,” released about a month after the shooting. The warrant application goes on to say Montgomery-Wilson and Powell “may have exchanged text messages concerning payment for Mack’s murder.” Montgomery-Wilson was arrested on an unrelated charge a few weeks after Mack’s death. A detective with the New Lenox police department then applied for and was granted a warrant to search the contents of his cellphone. Investigators then discovered a two-person text message conversation that mentioned “OTF” — the rap consortium founded by Lil Durk that prosecutors have linked to the alleged murder-for-hire plot in Los Angeles. On Feb. 10, 2022, one of the people in the text conversation asked, “Wassup with otf,” to which the other person responded, “Nothing.” Eight days later, in the same conversation, another text message read, “Did durk gave (sic) u that money.” In a statement last week, Banks’ attorneys blasted the prosecution’s focus on Lil Durk’s music and noted his yearslong record of philanthropy in Chicago. “When you see an artist’s rap lyrics quoted as ‘evidence’ against them, it is a glaring indication that there is no real evidence against that person,” Banks’ attorneys said in a statement to the Tribune. “The real truth is that Durk Banks is a Grammy Award-winning artist, a dedicated father and a loving husband,” Banks’ attorneys added. “Mr. Banks has been intensely committed to giving back to the Chicago community he loves through his Neighborhood Heroes Foundation and has put on more than a dozen charitable events over the last few years. He is looking forward to fighting against these false allegations in court.” In mid-October, federal authorities charged five others in a plot to kill rapper Quando Rondo — born Tyquian Terrel Bowman — in retaliation for the November 2020 shooting death of King Von. Banks is accused of bankrolling the effort to kill Bowman.. Bowman, his sister and his cousin, Saviay’a Robinson, 24, were riding in Bowman’s black Cadillac Escalade near a gas station in West Hollywood in August 2022 when gunmen opened fire, according to the federal charges. Bowman and his sister were not injured, but Robinson was struck multiple times and killed. ©2024 Chicago Tribune. Visit at chicagotribune.com . Distributed by Tribune Content Agency, LLC.Stran & Company Receives Additional Notification of Deficiency From Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

AMMO Deadline: POWW Investors Have Opportunity to Lead AMMO, Inc. Securities Fraud Lawsuit